Abbott Laboratories (ABT)
Health Care · Diversified Healthcare / Diagnostics & Pharmaceuticals
Abbott is a diversified healthcare conglomerate manufacturing diagnostics, nutritional products, pharmaceuticals, and medical devices with recent expansion into cancer diagnostics through Exact Sciences acquisition.
What Abbott Laboratories does
Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of healthcare products across four main segments: Established Pharmaceutical Products (branded generics marketed primarily in emerging markets), Diagnostic Products (laboratory and point-of-care testing systems), Nutritional Products, and Medical Devices. The company operates a global distribution network and is expanding into cancer diagnostics through a planned acquisition of Exact Sciences Corporation.
Themes: ["Diagnostics and laboratory testing","Point-of-care testing","Cancer diagnostics","Emerging markets pharmaceuticals","Global healthcare distribution","Medical devices","Biosimilars","Infectious disease testing"]
Fundamentals
- Price$94.40 as of 2026-07-09 close
- Market cap$164.5B as of 2026-07-10
- 1-year return-29.1% as of 2026-07-09 close
- P/E26.21 as of 2026-07-10
- Net margin+13.9% as of 2026-07-10
- Gross margin+56.5% as of 2026-07-10
- ROE+12.2% as of 2026-07-10
- Debt / equity0.65 as of 2026-07-10
- Revenue growth (YoY)+6.6% as of 2026-07-10
- Revenue CAGR (3y)+0.5% SEC XBRL
- Beta0.59 as of 2026-07-10
Dividend: yield +2.6%; 4-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Competitive pressures from generic drug substitution and introduction of competing branded and generic pharmaceutical products in the Established Pharmaceutical Products segment","Integration risks and regulatory approval uncertainty associated with the pending Exact Sciences Corporation acquisition","Foreign exchange exposure reflected in cumulative currency translation losses of $6.3 billion and negative comprehensive income adjustments in Q1 2026"]
Competitors & peers
- Roche (RHHBY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.